Recurrent Acute Otitis Media

Three or more distinct episodes of acute otitis media within 6 months, or four or more within 12 months with at least one episode in the preceding 6 months, with complete resolution of signs and symptoms between episodes. The requirement for interval resolution distinguishes it from chronic otitis media with effusion punctuated by exacerbations.

Mechanisms

• Persistent bacterial biofilm on middle ear mucosa and within adenoid tissue, which survives conventional antibiotic courses and reactivates with each viral illness.
• Immature or dysfunctional Eustachian tube function.
• Repeated viral upper respiratory infection acting as the trigger for each episode.
• Impaired mucosal immunity and reduced antibody responses to polysaccharide antigens in some children.

Risk factors

• First episode before 6 months of age, the strongest predictor.
• Day care attendance and older siblings.
• Absence of breastfeeding.
• Tobacco smoke exposure.
• Pacifier use beyond 6 months and supine bottle feeding.
• Cleft palate, submucous cleft, Down syndrome and craniofacial anomalies.
• Allergic rhinitis and adenoid hypertrophy.
• Immunodeficiency, including immunoglobulin A deficiency, immunoglobulin G subclass deficiency and specific polysaccharide antibody deficiency.
• Primary ciliary dyskinesia and cystic fibrosis.
• Gastro oesophageal reflux, with a weaker association.

• Repeated discrete episodes of otalgia, fever and irritability, each resolving with or without treatment.
• Normal tympanic membranes and normal hearing between episodes in true recurrent disease. Persisting effusion between episodes indicates a combined picture and shifts management toward tube insertion.
• Frequent antibiotic courses with rapid relapse after completion.
• Parental exhaustion, sleep disruption and repeated school or work absence, which are legitimate parts of the surgical indication.

Features that require investigation beyond the ear

• Concurrent recurrent sinopulmonary infection, chronic wet cough, bronchiectasis or failure to thrive, suggesting immunodeficiency or ciliary dysfunction.
• Neonatal respiratory distress in a term infant, situs inversus and chronic rhinorrhoea from birth, suggesting primary ciliary dyskinesia.
• Chronic nasal obstruction, mouth breathing, snoring and hyponasal speech, suggesting adenoid hypertrophy.
• Feeding difficulty, nasal regurgitation, bifid uvula or a notched hard palate, suggesting submucous cleft.

The first step is to confirm that the episodes are real. Parental report substantially overestimates frequency, and diagnoses made without otoscopy or without an effusion are frequently upper respiratory infections with referred otalgia.

• Review documented episodes with recorded otoscopic findings and treatment.
• Otoscopy or microscopy plus tympanometry between episodes, to determine whether the ear returns to normal or retains an effusion.
• Age appropriate audiometry.
• Nasoendoscopy to assess adenoid size and the nasopharynx.
• Examine the palate specifically for submucous cleft: bifid uvula, zona pellucida and a notched posterior hard palate.

Investigations for the child with severe or atypical disease

• Full blood count with differential.
• Serum immunoglobulins G, A and M with immunoglobulin G subclasses.
• Specific antibody titres to tetanus, diphtheria and pneumococcal serotypes before and 4 weeks after booster immunisation, to detect specific antibody deficiency.
• HIV testing.
• Sweat chloride testing and cystic fibrosis genetics where there is chronic respiratory disease or failure to thrive.
• Nasal nitric oxide screening and ciliary brush biopsy for primary ciliary dyskinesia.
• Middle ear fluid culture at the time of tympanocentesis or tube insertion to guide targeted therapy.

Modifiable risk factor reduction, which is the least expensive intervention and is frequently omitted

• Complete elimination of tobacco smoke exposure in the home and car.
• Continue breastfeeding for at least 6 months where possible.
• Feed upright rather than supine.
• Discontinue the pacifier after 6 months.
• Reduce day care exposure or change to a smaller setting where feasible.
• Treat allergic rhinitis with an intranasal corticosteroid such as mometasone 50 micrograms per nostril once daily in children aged 3 to 11 years, or fluticasone furoate 27.5 micrograms per nostril once daily from 2 years.
• Ensure complete pneumococcal conjugate vaccination and annual influenza vaccination. Influenza vaccination reduces episodes during the influenza season.

Management of individual episodes

• Treat each episode as acute otitis media with adequate analgesia and, given the recurrent pattern, with high dose co amoxiclav 90 mg/kg per day of the amoxicillin component divided twice daily for 10 days rather than plain amoxicillin, because beta lactamase producing organisms predominate in this group.
• Where a ventilation tube is in place, treat otorrhoea topically with ciprofloxacin 0.3 percent with dexamethasone 0.1 percent, 4 drops twice daily for 7 days, and reserve oral antibiotics for systemic illness or failure.

Antibiotic prophylaxis

• Largely abandoned as routine practice. The effect is modest, preventing roughly one episode per child per year, and it drives resistance and colonisation with resistant organisms.
• Where used in selected cases, such as during a winter season while awaiting surgery: amoxicillin 20 mg/kg orally once daily at night for 3 to 6 months. Review at intervals and stop if episodes continue.

Ventilation tube insertion

The principal surgical intervention.

• Indicated for three episodes in 6 months or four in 12 months, particularly where there is an effusion present at the time of assessment, where complications have occurred, or where the child has craniofacial anomalies, immunodeficiency or an only hearing ear.
• Reduces the frequency of episodes by approximately one to two per year and, importantly, converts subsequent episodes into painless otorrhoea treatable with topical drops rather than systemic antibiotics.
• Short term tubes are appropriate for the first insertion.
• Discuss the expected complications: otorrhoea in 10 to 25 percent, tympanosclerosis, blockage and a small risk of persistent perforation.

Adenoidectomy

• Considered in children aged 4 years and above, in those requiring a second set of tubes, and in any child with significant nasal obstruction or chronic adenoiditis.
• Removes the biofilm reservoir and mechanical obstruction of the tube.
• Contraindicated in overt or submucous cleft palate and in velopharyngeal insufficiency.

Additional considerations

• Tonsillectomy is not indicated for recurrent acute otitis media alone.
• Immunoglobulin replacement is reserved for confirmed antibody deficiency under specialist immunology supervision.
• Audiological review is essential, since repeated episodes may leave persistent conductive loss or unmask a sensorineural component.
• Warn families of the features of mastoiditis and intracranial complication and provide clear escalation instructions, since the recurrent group has the greatest cumulative exposure to these risks.

Follow up

Review 6 to 8 weeks after tube insertion with otoscopy and audiometry, then 6 monthly until the tubes extrude and stability is confirmed. Most children outgrow the tendency by 6 to 7 years as the Eustachian tube matures and viral exposure declines.